Abstract:The epidermal growth factor receptor (EGFR, erbB1, HER1) has been well-validated as a molecular target in anticancer drug discovery. In non-small-cell lung cancer patients (NSCLCs) harboring active mutations in the EGFR tyrosine kinase domain (L858R and del E746-A750), the first generation inhibitors, gefinitib and erlotinib, have achieved significant clinical benefits but emerging acquired resistance to them has become a major clinical challenge. The “gatekeeper” T790M mutation (threonine!methionine) of EGFR, by which the binding of ATP with the kinase is favored, is one of the primary mechanisms for resistance and plays a role in the circa 50 % of NSCLC patients who acquired clinical resistance. 7] Although the Cys797-chelating irreversible EGFR inhibitors displayed promising potential to overcome EGFR related resistance in animal models, their non-selective inhibition against wild-type EGFR (EGFR) and/or other kinases results in a relatively low maximal-tolerated-dose (MTD) and poor clinical outcomes in human patients. Inhibitors selectively targeting EGFR mutants are an attractive strategy for the clinical management of NSCLC patients with acquired resistance. However, because EGFR and the EGFR mutants share highly similar three-dimensional structures and have almost identical binding affinities with ATP, nearly all of the reported irreversible EGFR inhibitors displayed equal potencies against the T790M mutants and the wild-type enzyme, highlighting the challenge in the search for EGFR mutant-selective inhibitors. Only recently, WZ4002 was reported as a new irreversible EGFR inhibitor displaying moderate selectivity on EGFR mutants over the wild-type kinase. A phase I clinical trial was recently initiated on another moderately mutant-selective EGFR inhibitor CO-1686 (Kd(EGFR )/Kd(EGFR ) = 25, NCT01526928) whose chemical structure was not disclosed, and PKC412 was reported as a novel reversible T790M mutant-selective EGFR inhibitor with promising in vivo efficacy. Herein, we wish to report the successful discovery of novel pyrimido[4,5-d]pyrimidin-4(1H)-onebased EGFR inhibitors with more than 100-fold selectivity over the wild-type kinase. We have successfully designed compounds 1 and 2 (Scheme 1) as novel EGFR inhibitors with low nanomolar IC50 and Kd values. However, these compounds only displayed four-fold selectivity on EGFR mutants over EGFR. The use of conformational constraint is a general strategy with which to improve ligand selectivity for a molecular target, and accordingly a series of pyrimido[4,5d]pyrimidin-4(1H)-one derivatives 3 a–3h with more rigid conformations based on the structure-activity relationship (SAR) studies of compounds 1 and 2 (Scheme 1) were designed. The compounds were readily synthesized by using the similar procedures to that of 3a (Scheme 2; Supporting Information, Scheme S1). Briefly, a direct nucleophilic coupling of commercially available ethyl 2,4-dichloropyrimidine5-carboxylate (4) with tert-butyl-3-aminophenylcarbamate (5) produced ethyl 4-[{3-[(tert-butoxycarbonyl)amino]phenyl}amino]-2-chloropyrimidine-5-carboxylate (6). Hydrolysis of compound 6 with 1m NaOH in a H2O/THF mixed solution yielded the carboxylic acid (7). The condensation of 7 and 8a in the presence of HATU and DIPEA in dry CH2Cl2 gave the intermediate 9a. Compound 9a was coupled with aniline by nucleophilic substitution followed by deprotection with 50% trifluoroacetic acid in CH2Cl2 to yield the key precursor 10a. The new inhibitor 3a was finally obtained by acryloylation of 10a with acryloyl chloride. The binding affinities of the compounds with EGFR and its T790M mutants were determined with an active-sitedependent competition binding assay conducted by Ambit Bioscience, San Diego, USA. The kinase inhibitory activities of the compounds were also evaluated by the well-established [*] T. Xu, L. Zhang, S. Xu, J. Luo, F. Ding, X. Lu, Y. Liu, Z. Tu, Prof. D. Pei, Q. Cai, X. Ren, Prof. K. Ding Institute of Chemical Biology, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences 190 Kaiyuan Avenue, Guangzhou 510530 (China) E-mail: ding_ke@gibh.ac.cn T. Xu, S. Xu University of Chinese Academy of Sciences 19 Yuquan Road, Beijing 100049 (China)

Pyrimido[4,5-D]Pyrimidin-4(1h)-One Derivatives As Selective Inhibitors of Egfr Threonine(790) to Methionine(790) (t790m) Mutants

Discovery of N-((3r,4r)-4-Fluoro-1-(6-((3-Methoxy-1-Methyl-1h-Pyrazol-4-Yl)Amino)-9-M Ethyl-9h-Purin-2-Yl)Pyrrolidine-3-Yl)Acrylamide (Pf-06747775) Through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic Egfr Mutants with Selectivity over Wild-Type Egfr

Discovery of 1-{(3R,4R)-3-[5-Chloro-2-(1-methyl-1H-pyrazol-4-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxymethyl]-4-methoxy-pyrrolidin-1-yl}propenone (PF-06459988), A Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants.

Abstract 2078: CK-101 (RX518), a Mutant-Selective Inhibitor of EGFR That Overcomes T790M-mediated Resistance in NSCLC

The situation of nursing administrators in hospitals for the mentally handicapped: problems in measuring and evaluating the quality of care.

Discovery of a Novel Mutant-Selective Epidermal Growth Factor Receptor Inhibitor Using in silico Enabled Drug Discovery Platform

Overcoming EGFR(T790M) and EGFR(C797S) Resistance with Mutant-Selective Allosteric Inhibitors.

Discovery of 5-(Methylthio)pyrimidine Derivatives As L858R/T790M Mutant Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors.

Conformational Constrained 4-(1-Sulfonyl-3-indol)yl-2-phenylaminopyrimidine Derivatives as New Fourth-Generation Epidermal Growth Factor Receptor Inhibitors Targeting T790M/C797S Mutations

Discovery of (R)-1-(3-(4-amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) As a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode.

[Custom-made mouthguards and prevention of orofacial injuries in sports].

Discovery And Characterization Of A Novel Irreversible Egfr Mutants Selective And Potent Kinase Inhibitor Chmfl-Egfr-26 With A Distinct Binding Mode

2-Oxo-3,4-dihydropyrimido[4,5-d] Pyrimidines As New Reversible Inhibitors of EGFR C797S (cys797 to Ser797) Mutant

Design, synthesis and biological evaluation of aminopyrimidine derivatives bearing a 4,5,6,7-tetrahydrothieno [3,2-c]pyridine as potent EGFR inhibitors

Design, Synthesis, Anti-Tumor Activity, and Molecular Modeling of Quinazoline and Pyrido[2,3-D]Pyrimidine Derivatives Targeting Epidermal Growth Factor Receptor

A chemical tuned strategy to develop novel irreversible EGFR-TK inhibitors with improved safety and pharmacokinetic profiles.

Molecular Mechanism Study of EGFR Allosteric Inhibitors Using Molecular Dynamics Simulations and Free Energy Calculations

Discovery of novel 9-heterocyclyl substituted 9H-purines as L858R/T790M/C797S mutant EGFR tyrosine kinase inhibitors

Structure-Based Design of 5-Methylpyrimidopyridone Derivatives As New Wild-Type Sparing Inhibitors of the Epidermal Growth Factor Receptor Triple Mutant (EGFRL858R/T790M/C797S).

Variable time-space compliance control for human support

Discovery of highly potent and selective EGFRT790M/L858R TKIs against NSCLC based on molecular dynamic simulation